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The conjugative metabolism mediated by UDP-glucuronosyltransferase enzymes (UGTs)
significantly influences the bioavailability and biological responses of endogenous
molecule substrates and xenobiotics including drugs. UGTs participate in the regulation
of cellular homeostasis by limiting stress induced by toxic molecules, and by
controlling hormonal signaling networks. Glucuronidation is highly regulated at genomic,
transcriptional, post-transcriptional and post-translational levels. However, the UGT
protein interaction network, which is likely to influence glucuronidation, has received
little attention. We investigated the endogenous protein interactome of human UGT1A
enzymes in main drug metabolizing non-malignant tissues where UGT expression is
most prevalent, using an unbiased proteomics approach. Mass spectrometry analysis
of affinity-purified UGT1A enzymes and associated protein complexes in liver, kidney
and intestine tissues revealed an intricate interactome linking UGT1A enzymes to
multiple metabolic pathways. Several proteins of pharmacological importance such
as transferases (including UGT2 enzymes), transporters and dehydrogenases were
identified, upholding a potential coordinated cellular response to small lipophilic
molecules and drugs. Furthermore, a significant cluster of functionally related enzymes
involved in fatty acid β-oxidation, as well as in the glycolysis and glycogenolysis
pathways were enriched in UGT1A enzymes complexes. Several partnerships were
confirmed by co-immunoprecipitations and co-localization by confocal microscopy.
An enhanced accumulation of lipid droplets in a kidney cell model overexpressing
the UGT1A9 enzyme supported the presence of a functional interplay. Our work
provides unprecedented evidence for a functional interaction between glucuronidation
and bioenergetic metabolism.
Keywords: UGT, proteomics, protein-protein interaction, affinity purification, mass spectrometry, metabolism,
human tissues
Abbreviations:AP, affinity purification; UGT, UDP-glucuronosyltransferases; IP, immunoprecipitation; PPIs, protein-protein
interactions; UDP-GlcA, Uridine diphospho-glucuronic acid; ER, endoplasmic reticulum; MS, mass spectrometry.
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INTRODUCTION
UDP-glucuronosyltransferases (UGTs) are well known for their
crucial role in the regulation of cellular homeostasis, by limiting
stress induced by toxic drugs, other xenobiotics and endogenous
lipophilic molecules, and by controlling the hormonal signaling
network (Rowland et al., 2013; Guillemette et al., 2014). UGTs
coordinate the transfer of the sugar moiety of their co-substrate
UDP-glucuronic acid (UDP-GlcA) to amino, hydroxyl and thiol
groups on a variety of lipophilic molecules, thereby reducing
their bioactivity and facilitating their excretion. In humans,
nine UGT1A and ten UGT2 enzymes constitute the main
glucuronidating enzymes. UGTs are found in nearly all tissues,
each UGT displaying a distinct profile of tissue expression,
and are most abundant in the liver, kidney and gastrointestinal
tract, where drug metabolism is highly active. These membrane-
bound enzymes localized in the endoplasmic reticulum (ER)
share between 55 and 97% sequence identity, thus displaying
substrate specificity and some overlapping substrate preferences
(Rowland et al., 2013; Guillemette et al., 2014; Tourancheau
et al., 2016). For instance, the alternative first exons of the single
UGT1 gene produce the nine UGT1A enzymes with distinct
N-terminal substrate binding domains but common C-terminal
UDP-GlcA-binding and transmembrane domains. The seven
UGT2B enzymes and UGT2A3 are encoded by eight distinct
genes, whereas UGT2A1 and UGT2A2 originate from a single
gene by a UGT1A-like, alternative exon 1 strategy. However,
similar to UGT1As, substrate binding domains of UGT2 enzymes
are more divergent than their C-terminal domains.
Genetic variations, epigenetic regulation, as well as post-
transcriptional and translational modifications, all contribute to
the modulation of UGT conjugation activity, thereby influencing
an individual’s response to pharmacologic molecules and the
bioactivity of endogenous molecules (Guillemette et al., 2010,
2014; Ramírez et al., 2010; Hu et al., 2014; Dluzen and Lazarus,
2015). For instance, genetic lesions at the UGT1 locus that
impair UGT1A1 expression or activity result in transient or fatal
hyperbilirubinemia, characterizing Gilbert and Crigler-Najjar
syndromes, respectively (Costa, 2006).
Several lines of evidence support protein-protein interactions
(PPIs) among UGTs and with other enzymes of pharmacological
importance (Taura et al., 2000; Fremont et al., 2005; Takeda
et al., 2005a,b, 2009; Ishii et al., 2007, 2014; Operaña and Tukey,
2007). These interactions may also significantly influence UGT
enzymatic activity (Bellemare et al., 2010b; Ménard et al., 2013;
Ishii et al., 2014; Fujiwara et al., 2016). In addition, interactions
of UGT proteins with some anti-oxidant enzymes that have
been recently uncovered have raised the interesting concept of
alternative functions of UGTs in cells (Rouleau et al., 2014).
However, most studies have been conducted in cell-based systems
with overexpression of tagged UGTs and little evidence in
human tissues supports the extent of this mechanism and its
physiological significance.
PPIs are essential to cell functions including responses
to extracellular and intracellular stimuli, protein subcellular
distribution, enzymatic activity, and stability. Understanding
molecular interaction networks in specific biological contexts
is therefore highly informative of protein functions. We aimed
to gain insight on the endogenous protein interaction network
of UGT1A enzymes by applying an unbiased proteomics
approach in main drug metabolizing human tissues. In doing
so, we provide support to a potential coordinated cellular
response to small lipophilic molecules and drugs. Importantly,
a potential functional interplay between UGT1A enzymes and
those of bioenergetic pathways also emerges from this exhaustive
endogenous interaction network.
MATERIALS AND METHODS
UGT1A Enzyme Antibodies
The anti-UGT1A rabbit polyclonal antibody (#9348) that
specifically recognizes UGT1A enzymes, and not the alternative
UGT1A variant isoforms 2, has been described (Bellemare
et al., 2011). Purification was performed using the biotinylated
immunogenic peptide (K520KGRVKKAHKSKTH533; Genscript,
Piscataway, NJ, USA) and streptavidin magnetic beads
(Genscript) per the manufacturer’s instructions. Antibodies
(3 ml) were incubated O/N at 4◦C with peptide-streptavidin
beads, and then washed with PBS to remove unbound
immunoglobulins. UGT1A-specific antibodies were eluted
using glycine (0.125 M, pH 2.9), and rapidly buffered with Tris
pH 8.0. Purified antibodies were subsequently concentrated
using a centrifugal filter unit (cut off 3 kDa; Millipore (Fisher
Scientific), Ottawa, ON) to a final volume of 1 ml.
Affinity Purification of Endogenous UGT1A
Enzymes and Their Interacting Partners in
Human Tissues and a UGT1A Expressing
Cellular Model
Human liver, kidney and intestine S9 fractions comprised of ER
and associated membranes as well as cytosolic cellular content
(Xenotech LLC, Lenexa, KS, USA) were from 50, 4, and 13
donors, respectively. This study was reviewed by the local ethics
committee and was exempt given that anonymized human tissues
were from a commercial source. Human colon cancer HT-
29 cells (ATCC, Manassas, VA, USA) were grown in DMEM
supplemented with 10% fetal bovine serum (Wisent, St-Bruno,
QC, Canada), 50mg/ml streptomycin, 100 IU/ml penicillin, at
37◦C in a humidified incubator with 5% CO2 as recommended
by ATCC. Immunoprecipitations (IP) were conducted according
to standard procedures (Savas et al., 2011; Ruan et al., 2012),
with at least three independent replicates per sample source.
For each sample, 1mg protein was lysed in 1 ml lysis buffer
A [final concentration: 50mM Tris-HCl pH 7.4, 150mM NaCl,
0.3% deoxycholic acid, 1% Igepal CA-630 (Sigma-Aldrich), 1mM
EDTA, complete protease inhibitor (Roche, Laval, QC, Canada)]
for 45 min on ice. This buffer included deoxycholate to enhance
membrane solubilization and stringency of immunoprecipitation
conditions. Lysates were then homogenized by pipetting up and
down through fine needles (18G followed by 20G) 10–20 times
on ice. Lysates were cleared of debris by centrifugation for 15
min at 13,000 g. UGT1A enzymes were immunoprecipitated
from cleared lysates with 4 µg of purified anti-UGT1A for 1 h
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at 4◦C with end-over-end agitation. After addition of protein
G–coated magnetic beads (200µl Dynabeads, Life Technologies,
Burlington, ON), lysates were incubated O/N at 4◦C. Beads were
washed three times with 1ml lysis buffer A and subsequently
processed for mass spectrometry (MS) analysis, as described
below. Control IPs were conducted in similar conditions using
4 µg normal rabbit IgGs (Sigma-Aldrich) per protein sample.
The inclusion of 150 mM NaCl and 0.3% deoxycholate ensured
stringent wash conditions.
Liquid Chromatography-MS/MS
Identification of UGT1A Interacting
Partners
Protein complexes bound to magnetic beads were washed 5
times with 20 mM ammonium bicarbonate (1 ml). Tryptic
digestion and desalting was performed as described (Rouleau
et al., 2016). Briefly, bead-bound proteins were digested in
10µg/µl trypsin for 5 hrs at 37◦C. The tryptic digest was
recovered, dried, and resuspended in 30µl sample buffer
(3% acetonitrile, 0.1% trifluoroacetic acid, 0.5% acetic acid).
Peptides were desalted on a C18 Empore filter (ThermoFisher
Scientific), dried out, resuspended in 10µl 0.1% formic acid
and analyzed using high-performance liquid chromatography-
coupled MS/MS on a LTQ linear ion trap-mass spectrometer
equipped with a nanoelectrospray ion source (Thermo Electron,
San Jose, CA, USA) or on a triple-quadrupole time-of-flight
mass spectrometer (TripleTOF 5600, AB Sciex, Concord, ON)
as described (Rouleau et al., 2014). Data files were submitted
for simultaneous searches using Protein Pilot version 4 software
(AB Sciex) utilizing the Paragon and Progroup algorithms
(Shilov). The RAW or MGF file created by Protein Pilot
was used to search with Mascot (Matrix Science, London,
UK; version 2.4.1). Mascot was set up to search against the
human protein database (Uniref May 2012; 204083 entries)
supplemented with a complete human UGT protein sequence
database comprised of common UGT coding variations and
protein sequences of newly discovered alternatively spliced UGT
isoforms (assembled in-house November 2013; 882 entries).
Mascot analysis was conducted using the following settings:
tryptic peptides, fragment and parent ion tolerance of 0.100Da,
deamidation of asparagine and glutamine and oxidation of
methionine specified as variable modifications, deisotoping was
not performed, two missed cleavage were allowed. Mass spectra
were also searched in a reversed database (decoy) to evaluate
the false discovery rate (FDR). On-beads digestion and MS
analyses were performed by the proteomics platform of the
CHU de Québec Research Center. The MS proteomics data
have been deposited to the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org) via the PRIDE
partner repository with the dataset identifier PXD000295.
Identification of proteins in Scaffold (version 4.6.1; Proteome
Software, Portland, OR) was carried out using two sets of criteria:
(1) for UGT proteins, 95% peptide and protein probability, and 1
unique peptide were used, considering the high level of sequence
identity among the proteins in this family. For the same reason
of high sequence identity, each identified peptide was manually
assigned to the proper UGT protein or to the common UGT
sequence (Supplementary Table 1). (2) For UGT1A interacting
proteins, specificity threshold was set to 95% peptide and protein
probability and a minimum of 2 unique peptides. Proteins that
contained similar peptides and could not be differentiated based
on MS/MS analysis alone were grouped to satisfy the principles
of parsimony. Detailed proteomics datasets are provided in
Supplementary Tables 4–7.
Confidence scores of each UGT1A-protein interaction were
determined using the computational tools provided online
at http://crapome.org (Choi et al., 2011). Spectral counts
for each identified protein were normalized to the length of
the protein and total number of spectra in the experiment.
Two empirical scores (FC-A and more stringent FC-B) and
one probability score (SAINT) (Mellacheruvu et al., 2013)
were then calculated based on normalized spectral counts of
identified proteins in UGT1A immunoprecipitation samples
compared to our matching control immunoprecipitation
samples (CRAPome Workflow 3). Confidence score calculations
were conducted separately for each tissue, with the following
analysis options: FC-A: Default parameters; FC-B: User
controls, stringent background estimation, geometric combining
replicates; SAINT: User Controls, Average - best 2 Combining
replicates, 10 Virtual controls and default SAINT options.
Confidence scores for all UGT1A interaction partners are given
in Supplementary Table 2.
Bioinformatics Tools and Data Analysis
The common external contaminants keratins and trypsin were
manually removed from the lists of interacting proteins prior
to pathway enrichment analysis. UGT1A interacting partners
were classified according to KEGG pathways (update November
12, 2016) using ClueGO and CluePedia Apps (v2.3.2) in
Cytoscape 3.4 (Bindea et al., 2009, 2013). Enrichment was
determined based on a two-sided hypergeometric statistical test
and a Bonferroni step down correction method. Only enriched
pathways with P < 0.05 and a Kappa score threshold of 0.4
were considered. The following optional criteria were also used
for the search: minimum # genes = 4, minimum 2% genes.
The UGT1A interactome was generated using Cytoscape basic
tools. Because protein annotations based on tools such as KEGG
and Gene Ontology are partial, the UGT1A interactome was
subsequently manually extended to include significant UGT1A
interactors that were absent in the original output but involved in
enriched pathways, per their Uniprot entries (www.uniprot.org)
and literature mining. Details are included in the legend of
Figure 3.
Validation of Protein-Protein Interactions
by Co-IP and Immunofluorescence (IF)
HEK293 cells stably expressing the human enzyme UGT1A9-
myc/his (a pool of cells) were used (Bellemare et al., 2010a).
Expression and glucuronidation activity of the tagged UGT1A9
in this model have been described and were similar to the
untagged enzyme (Bellemare et al., 2010a). In the current
study, only the myc tag served for UGT1A9 detection and
the his tag was not exploited. Cells were transfected with
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Lipofectamine 2000 (Life Technologies) to transiently express
tagged protein partners. HA-ACOT8 and FLAG-SH3KBP1 were
kindly provided by Dr Ming-Derg Lai (National Cheng Kung
University, Taiwan; Hung et al., 2014) and Dr Mark McNiven
(Mayo Clinic, Rochester, MN; Schroeder et al., 2010) respectively.
The PHKA2-myc-FLAG expression construct was purchased
from OriGene (Rockville, MD, USA).
Co-IP: HEK293 cells (3 × 105 cells plated in 10 cm
dishes) were harvested 40 h post-transfection. Cells were
washed three times with PBS, lysed in 800µl lysis buffer
B (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Igepal,
1mM DTT, complete protease inhibitor) for 1 h at 4◦C and
subsequently homogenized and centrifuged as described above.
Immunoprecipitation with purified anti-UGT1A antibodies
(2 µg) or control rabbit IgG (2µg) and 50µl Protein-
G magnetic beads was as above. Protein complexes were
washed three times in lysis buffer B and eluted in Laemmli
sample buffer by heating at 95◦C for 5 min. Eluates were
subjected to SDS-PAGE, and the presence of interacting partners
was revealed by immunoblotting using anti-tag antibodies
specified in figures and legends: anti-myc (clone 4A6, EMD
Millipore, Etobicoke, ON, Canada; 1:5000), anti-FLAG (clone
M2, Sigma-Aldrich, St-Louis, MO, USA; 1:20 000) and anti-
HA (Y-11, Santa Cruz Biotechnologies, Dallas, TX, USA;
1:500).
IF: HEK293 cells (2 × 105 cells per well of 6-well plates)
grown on coverslips were harvested 36 h post-transfection
and processed for IF, as described (Rouleau et al., 2016).
ACOT8 was detected with anti-HA (1:500), SH3KBP1 with
anti-FLAG (1:1500), UGT1A9-myc/his with anti-myc (1:200)
or purified anti-UGT1A (1:500), and with secondary goat anti-
rabbit, goat anti-mouse or donkey anti-mouse respectively,
conjugated to either AlexaFluor 488 or 594 (1:1000; Invitrogen).
Immunofluorescence images were acquired on a LSM510 META
NLO laser scanning confocal microscope (Zeiss, Toronto, ON,
Canada). Zen 2009 software version 5.5 SP1 (Zeiss) was used for
image acquisitions.
Quantification of Lipid Droplets
HEK293 cells grown on coverslips were fixed in 3.7%
formaldehyde (Sigma) for 30 min at RT. Cells were then gently
washed three times with PBS and incubated for 10min in
0.4µg/mL Nile Red (Sigma). After being rinsed three times,
coverslips were mounted on glass slides using Fluoromount
(Sigma) as a mounting medium. Images were acquired on
a Wave FX-Borealis (Quorum Technologies, Guelph, ON,
Canada) - Leica DMI 6000B (Clemex Technologies inc.,
Longueil, QC, Canada) confocal microscope, with a 491 nm
laser and 536 nm filter. Z-stacks were acquired every 0.15µm.
Stacks were analyzed using ImageJ (v1.51f; U.S. National
Institutes of Health, Bethesda, MD, USA) and the 3-D Object
Counter plugin (Bolte and Cordelieres, 2006). Results are
derived from 3 independent experiments and more than
140 cells per experiment were analyzed for each condition.
Fluorescence images were acquired on an LSM 510 microscope
as above.
FIGURE 1 | UGT1A interaction network investigated by untargeted
proteomics. (A) The nine UGT1A enzymes are distinguished by the amino
acid sequence of their substrate binding domain (unique peptides) whereas
they share identical C-terminal co-substrate and transmembrane domains
(common peptides). The anti-UGT1A antibody used in this study was raised
against a C-terminal peptide common to all nine UGT1A enzymes but does
not recognize the main spliced alternative isoforms 2 or UGT1A_i2s. (B)
Experimental approach to establish endogenous UGT1A protein interactomes
in drug metabolizing tissues and in the colon cancer cell model HT-29.
Immunoprecipitation of UGT1A enzymes was conducted with the anti-UGT1A
antibody. The numbers of common and unique UGT1A protein partners
identified by mass spectrometry and above confidence threshold are
represented in the Venn diagrams. Datasets were established on a minimum of
two biological replicates. A Venn diagram for the 4 matrices is presented in
Supplementary Figure 2. A list of proteins in each group is provided in
Supplementary Table 3.
RESULTS
Endogenous UGT1A Enzymes Associate
with Several Other Metabolic Proteins in
Non-malignant Human Tissues
The endogenous interactome of human UGT1A enzymes was
established in three major metabolic tissues, namely liver, kidney
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FIGURE 2 | Quantitative overview of UGT1A enzymes immunoprecipitated from each tissue. Identification of immunoprecipitated UGT1A enzymes was
based on the detection of peptides unique to specified UGT1A enzymes. (A) The quantitative assessment of each immunoprecipitated UGT1A is given by the total
number of spectral counts for peptides unique to each UGT1A identified by mass spectrometry. Total spectral counts for peptides common to all UGT1A enzymes
(Liver: 465; Kidney: 67; Intestine: 1561) were not considered in the quantitative assessment of specific UGT1As. (B) For each tissue, the number of peptides unique to
each UGT1A identified by MS/MS analysis is represented in ring charts. Detailed quantification and unique/common UGT1A peptides identified are presented in
Supplementary Table 1.
and intestine from pools of 4–50 donors, using S9 tissue fractions
comprised of ER and associated membranes as well as cytosolic
cellular content (Figure 1). IPs were conducted with an antibody
specific to the C-terminal region common to the nine human
UGT1A enzymes, thereby allowing affinity purification of all
UGT1A enzymes expressed in studied tissues (Figure 1A). This
antibody was shown by western blotting to lack affinity for
alternatively spliced UGT1A isoform 2 proteins derived from
the same human UGT1 gene locus (Bellemare et al., 2011).
The experimental approach to establish the endogenous UGT1A
enzymes interactome using the anti-UGT1A enzymes antibody is
presented in Figure 1B.
Multiple UGT1A enzymes were immunopurified from
each tissue in line with their documented expression
profile (Figure 2). The list of specific UGT1A enzymes
immunoprecipitated from each tissue was established based
on their unique N-terminal peptide sequences, whereas
multiple additional peptides corresponding to the common C-
terminal half of the UGT1A proteins and thereby common
to all UGT1A enzymes were also observed (Figure 2B,
Supplementary Figure 1; Supplementary Table 1).
Spectral counts for unique peptides provided a quantitative
appreciation of immunoprecipitated UGT1A (Figure 2A).
UGT1A1 and UGT1A4 were the most abundant UGT1As
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TABLE 1 | Top 10 UGT1A interaction partnersa for each tissue based on confidence score.
Liver Kidney Intestine
Protein
nameb
Coverage
(%)c
Total spectral
countsd
FC_B
score
Protein
nameb
Coverage
(%)c
Total spectral
countsd
FC_B
score
Protein
nameb
Coverage
(%)c
Total spectral
countsd
FC_B
score
PHKB 36 193 28.55 TOP2B 16 53 5.93 ATP5A1 13 8 4.91
PHKA2 34 180 26.62 PFKL 24 35 4.68 UGT2A3 24 61 4.63
PHKG2 40 68 10.49 TRA2B 24 36 4.21 GBF1 12 60 4.60
PRDX2 47 55 7.62 ATP5A1 33 32 4.10 SLC25A5 35 54 4.37
UGT2B7 19 31 5.53 PRDX2 41 50 3.60 RALGAPB 13 51 4.26
PRDX1 35 25 3.42 PRDX1 44 39 3.08 PRDX2 24 46 4.06
ECH1 28 17 2.61 HSPA8 30 21 2.70 PRDX1 31 45 4.01
SLC25A5 17 9 2.20 SLC34A2 16 17 2.66 RALGAPA2 6 29 3.28
GBF1 4 9 2.15 ACCA2 43 21 2.30 ECH1 30 21 2.84
UGT2B4 11 12 1.98 ASS1 42 21 2.22 PDIA3 5 3 2.82
aExcluding common IP protein contaminants (structural, ribosomal and RNA-binding proteins).
bProteins in bold were identified in the 3 tissues.
cTotal coverage calculated with peptides identified in all replicates (n = 4, 3 and 2 for the liver, kidney and intestine, respectively).
dTotal spectral counts of all replicates.
in hepatic IPs, whereas UGT1A1 and UGT1A10 were
predominantly immunopurified from the intestine and UGT1A9
from the kidney (Figure 2A, Supplementary Table 1). UGT1A9
(n = 51 spectra) was far more abundant than UGT1A6 (n = 2
spectra) in the kidney whereas UGT1A10 (n = 194 spectra)
predominated over most other UGT1A in the intestine,
although all UGT1A enzymes were identified besides UGT1A7
and UGT1A9. These metrics indicated that an exhaustive
immunoprecipitation of UGT1As from each tissue was achieved.
UGT1A Interaction Network and Functional
Annotation
A total of 9 independent AP-MS datasets (4 liver, 3 kidney,
and 2 intestine replicates of control and UGT1A AP-MS)
efficiently immunoprecipitated UGT1A enzymes and associated
proteins. Mass spectra were assigned to specific proteins using
Mascot and Scaffold software. A list of UGT1A-interacting
proteins was created based on the analysis of total spectral
counts assigned to each identified protein in each replicate to
obtain empirical (FC-B) and probability (SAINT) confidence
scores (Supplementary Table 2). Using a FC-B score threshold
of 1.42, we reported a total of 148 proteins forming endogenous
interactions with UGT1A enzymes in the three surveyed
human tissues (31 in the liver, 70 in the kidney and 77 in
the intestine) (Figure 1B, Supplementary Table 2). This FC-
B threshold was selected based on the validated protein
partner having the lowest probability score, corresponding to
PHKA2 in the intestine (see below). This approach was chosen
because of the inherent difficulty to obtain similar replicate
datasets with AP-MS from tissues, especially in intestine, a
variability highly penalized in the SAINT scoring algorithm
(Supplementary Figure 2). To further strengthen the UGT1A
interactome in the gastrointestinal tract, we also conducted
three more replicate AP-MS experiments of endogenous UGT1A
enzymes with the human colon cancer cell line HT-29,
expressing high levels of UGT1As. The intestinal UGT expression
profile is well represented in HT-29 cells, with UGT1A1,
UGT1A6, UGT1A8, and UGT1A10 immunoprecipitated in
similar proportions (Supplementary Table 1). Using the FC-B
threshold used for tissues (1.42), 125 interaction partners were
selected for further analysis. Of those, 44 proteins were common
with those immunoprecipitated in non-malignant tissue samples,
including 26 common with the intestine dataset (Figure 1B,
Supplementary Figure 3). UGT1A protein partners with highest
significance scores are given in Table 1 whereas a complete
list of immunoprecipitated protein partners is provided in
Supplementary Table 2.
To portray the global functions enriched in the UGT1A
interactome, the UGT1A protein partners from the three
surveyed tissues were classified per the KEGG pathway
database. Structural proteins such as tubulins, myosins, actin,
as well as multiple ribosomal protein subunits (RPL/RPS
proteins) and other RNA-binding proteins involved in mRNA
splicing (e.g., heterogeneous ribonucleotide proteins (hnRNPs)
and serine/arginine-rich splicing factors (SRSF) proteins)
were significant classes of proteins immunoprecipitated
with UGT1As. However, because these proteins are
frequently non-specifically enriched in AP-MS experiments
(Mellacheruvu et al., 2013), the specificity of interactions
with UGT1A will require validation and will not be discussed
further.
The interactome of UGT1A enzymes is characterized by
numerous metabolic proteins playing roles in detoxification
and bioenergetic pathways (Figure 3). They include the UGT2
glucuronosyltransferases UGT2A3, UGT2B4, UGT2B7, and
UGT2B17, the glutathione S-transferase GSTA1, glycine N-
acyltransferase GLYAT, the alcohol dehydrogenase ALDH2 and
the antioxidant enzymes PRDX1 and PRDX2 (full protein names
are provided in Table 2). Given their functions in line with
high scoring proteins, ADH1B and PRDX3 were also included
in the final interactome, having confidence interaction scores
just below threshold (FC-B = 1.37; Supplementary Figure 2).
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FIGURE 3 | UGT1A interaction network in drug metabolizing tissues. UGT1A interacting proteins were classified according to KEGG pathways with
ClueGO/CluePedia (Bindea et al., 2009, 2013). Node size is representative of pathway enrichment significance. Interactome was enhanced with significant interaction
partners not part of KEGG pathways that are functionally related based on Uniprot and literature. These proteins are not linked to nodes but are grouped according to
global functions. Structural proteins, ribosomal protein subunits and other RNA-binding proteins involved in mRNA splicing are not shown but were significantly
enriched in UGT1A IPs. Full protein names are provided in Table 2. Complete lists of UGT1A interacting proteins are provided in Supplementary Table 2.
Similarly, the cytochrome P450 CYP3A4 was included because
also observed in liver tissue with a single high confidence peptide
and a previously observed interaction partner (Fremont et al.,
2005; Ishii et al., 2014). Enzymes of the lipid metabolism pathway
were also significantly represented and most particularly
several peroxisomal and mitochondrial proteins involved
in fatty acid β-oxidation, namely ACOT8, ECH1, CPT1A,
and ACAA2. To encompass all potential protein partners
involved in lipid metabolism, a pathway that was functionally
validated at a later stage (see below), relevant but slightly lower
scoring proteins were incorporated in the final interactome,
namely SCP2, ACSL1, EHHADH, ACAT1, and ECHS1
(FC-B = 1.38–1.19; Supplementary Figure 2). Finally, the
glycolysis/pyruvate and glycogenolysis metabolic pathways
were also significantly enriched, given the high number of
immunoprecipitated UGT1A partners in these pathways. Several
other protein partners, including transporters (SLC25A5,
SLC25A13, and SLC34A2) and proteins participating in
vesicular trafficking (RALGAPA1, RALGAPA2, RALGAPB,
and GBF1) were also immunoprecipitated from tissues and
may represent important partners (Table 1, Figure 3). The
interaction network of UGT1A enzymes established in the
HT-29 cell model was consistent with that built from tissues,
with enrichments in xenobiotic and bioenergetics metabolic
pathways. Several transporters, anti-oxidant, lipid metabolism,
glycolytic/glycogen metabolic enzymes and vesicular trafficking
proteins were all significantly identified in AP-MS on cells,
as in tissues (Supplementary Table 2), further supporting
the significance of the endogenous interactome of UGT1A
enzymes.
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FIGURE 4 | Validation of selected protein interactions by immunoprecipitation and immunofluorescence in a UGT negative kidney cell model.
(A) Immunoprecipitation (IP) of UGT1A9, with purified anti-UGT1A antibodies, was conducted in HEK293-UGT1A9_myc/his transiently transfected with the indicated
protein partner. UGT1A9 was immunodetected with anti-myc, whereas protein partners were detected with anti-tag antibodies as specified below immunoblots.
Control IPs were conducted with normal rabbit immunoglobulins (IgG). Lysates (IP input) are shown as references. Protein bands denoted by the asterisk are the
rabbit IgGs used in IPs. (B) Co-localization of UGT1A9 and the protein partners ACOT8 and SH3KBP1/CIN85 assessed by immunofluorescence in
HEK293-UGT1A9_myc/his transiently expressing specified partners. Confocal microscope images are representative of three independent experiments. Partial
co-localization is detected by yellow labeling in merged images. Insets present enlargements of boxed regions in merged images. Bar = 20µm.
Experimental Validation of Selected UGT1A
Partners
Using the non-malignant kidney model cell line HEK293 (a UGT
negative model) stably expressing a myc/his-tagged UGT1A9
enzyme, selected partnerships with enzymes of bioenergetic
cellular pathways were confirmed by a co-IP/immunodetection
approach. The peroxisomal acyl-coenzyme A thioesterase
ACOT8, involved in fatty acid β-oxidation, and the cytosolic
phosphorylase b kinase regulatory subunit A2 (PHKA2),
involved in glycogen degradation, were selected based on their
significant enrichment in more than one tissue (ACOT8 in
kidney, intestine and HT-29; PHKA2 in all 4 matrices). The
cytosolic SH3 domain-containing kinase-binding protein 1, also
known as cbl-interacting protein of 85 kDa (SH3KBP1/CIN85),
an adaptor protein regulating membrane trafficking and receptor
signaling, was also chosen as a representative protein partner
of the vesicular trafficking pathway, given its identification in
the kidney and HT-29 datasets. After transient expression of
selected partners as tagged proteins in the kidney cell model
stably expressing UGT1A9, each of the candidate partners
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FIGURE 5 | Accumulation of cellular lipid droplets in UGT1A9 expressing HEK293 cells. (A) Representative images of lipid droplets (green fluorescence)
stained with Nile Red in HEK293-UGT1A9_myc-his or control HEK cells (stably transfected with the empty pcDNA3.1 vector—UGT negative cells). Bar = 20µm.
(B) Average number of lipid droplets per cell stably expressing UGT1A9 or control HEK cells. Lipid droplets per cell were counted in at least 140 cells per condition
and averaged (n = 3 independent experiments).
was specifically enriched by an IP of UGT1A (Figure 4A).
Likelihood of a physical interaction of ACOT8 and CIN85
with UGT1A enzymes was further supported by their partial
co-localization with UGT1A9 detected by IF and confocal
microscopy (Figure 4B).
Influence of UGT1A on Cellular Lipid
Droplets
Pathway enrichment analysis identified several proteins involved
in lipid metabolism and suggested a possible functional
implication of UGT1A enzymes in this pathway. This was
explored by measuring levels of lipid droplet in HEK293 cells
stably expressing or not the UGT1A9 enzyme. Lipid droplets,
cytoplasmic organelles that constitute a store of neutral lipids
such as triacylglycerides, were labeled with Nile Red and counted.
This analysis revealed that the number of lipid droplets per cell
was significantly higher in UGT1A9-expressing cells relative to
control cells (by 7.5-fold, P < 0.001), whereas average size and
staining intensity of lipid droplets were similar between UGT
negative and UGT1A9-expressing HEK293 cells (Figure 5).
DISCUSSION
Defining protein interaction networks is a key step toward
a better understanding of functional crosstalk among cellular
pathways. In the current work, we established the endogenous
interactome of key metabolic UGT1A enzymes in three
relevant human tissues. Data suggest an interplay between
UGT1A enzymes regulating the glucuronidation pathway and
enzymes involved in multiple cellular energetic pathways,
most notably with lipid and glucose/glycogen metabolism.
This interactome considerably expands what was known
about UGT1A protein interactions in the literature (reviewed
by Ishii et al., 2010; Fujiwara et al., 2016) and public
databases (3 interactions among UGT1A enzymes reported in
STRING database (http://string-db.org/), none in the iRefWEB
database (http://wodaklab.org/iRefWeb/), accessed November 9,
2016).
One of our study’s strength relies on the use of an unbiased
approach targeting endogenous proteins in non-malignant
human tissues, as opposed to most studies that used the
overexpression of an exogenous tagged protein expressed in
a cellular model (Taura et al., 2000; Takeda et al., 2005a,b,
2009; Fujiwara et al., 2007a,b, 2010; Kurkela et al., 2007).
In addition, profiles of immunoprecipitated UGT1A enzymes
replicated well their known tissue distribution, and spectral
peptide counting further reflected the relative abundance of these
UGT1A enzymes previously established by mass spectrometry-
basedmultiple reactionmonitoring and RNA-sequencing (Fallon
et al., 2013a,b; Sato et al., 2014; Margaillan et al., 2015a,b;
Tourancheau et al., 2016). Of note, our data support the notion
that both UGT1A8 and UGT1A10 enzymes are expressed in
the intestine, as peptides unique to each UGT were detected
(Figure 2; Supplementary Table 1) (Strassburg et al., 2000; Sato
et al., 2014; Fujiwara et al., 2016; Troberg et al., 2016). Moreover,
two peptides specific to the UGT1A5 enzyme sequence were
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TABLE 2 | Complete names of most significant UGT1A protein partnersa.
Protein Namesb
Abbreviation Complete names
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial
ACAT1/SOAT1 Sterol O-acyltransferase 1
ACOT8 Acyl-coenzyme A thioesterase 8
ACSL1 Long-chain-fatty-acid–CoA ligase 1
ADH1B Alcohol dehydrogenase 1B
ALDH2 Aldehyde dehydrogenase, mitochondrial
ALDH6A1 Methylmalonate-semialdehyde dehydrogenase [acylating],
mitochondrial
ASS1 Argininosuccinate synthase
ATP5A1 ATP synthase subunit alpha, mitochondrial
CALM1 Calmodulin
CPT1A Carnitine O-palmitoyltransferase 1, liver isoform
CYP3A4 Cytochrome P450 3A4
ECH1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial
ECHS1 Enoyl-CoA hydratase, mitochondrial
EHHADH Peroxisomal bifunctional enzyme
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GBF1 Golgi-specific brefeldin A-resistance guanine nucleotide
exchange factor 1
GLYAT Glycine N-acyltransferase
GSTA1 Glutathione S-transferase A1
HSPA8 Heat shock cognate 71 kDa protein
IDH2 Isocitrate dehydrogenase [NADP], mitochondrial
ITPR2 Inositol 1,4,5-trisphosphate receptor type 2
PC Pyruvate carboxylase, mitochondrial
PCK2 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial
PDIA3 Protein disulfide-isomerase A3
PFKL ATP-dependent 6-phosphofructokinase, liver type
PHKA2 Phosphorylase b kinase regulatory subunit alpha, liver isoform
PHKB Phosphorylase b kinase regulatory subunit beta
PHKG2 Phosphorylase b kinase gamma catalytic chain, liver/testis
isoform
PKM Pyruvate kinase
PRDX1 Peroxiredoxin-1
PRDX2 Peroxiredoxin-2
PRDX3 Peroxiredoxin-3
RALGAPA1 Ral GTPase-activating protein subunit alpha-1
RALGAPA2 Ral GTPase-activating protein subunit alpha-2
RALGAPB Ral GTPase-activating protein subunit beta
SCP2 Non-specific lipid-transfer protein
SH3KBP1 SH3 domain-containing kinase-binding protein 1
SLC25A13 Calcium-binding mitochondrial carrier protein Aralar2
SLC25A5 ADP/ATP translocase 2
SLC34A2 Sodium-dependent phosphate transport protein 2B
TOP2B DNA topoisomerase 2-beta
TRA2B Transformer-2 protein homolog beta
aComplete list of immunoprecipitated proteins is provided in Supplementary Table 2.
bProtein names are according to Uniprot (www.uniprot.org; accessed December 21,
2016).
detected in the intestine, albeit at low levels (1 spectrum for
each peptide) relative to other expressed UGT1As, providing
evidence for its intestinal expression at the protein level
(Supplementary Figure 4).
We provide unprecedented data on protein-protein
interactions within the UGT family, namely between UGT1A
and UGT2A3 enzymes and/or UGT2B family members.
UGT1A-UGT2 interactions were observed in the liver (UGT2B4
and UGT2B7), in the kidney (UGT2B7) and in the intestine
(UGT2B7, UGT2B17, and UGT2A3), and reflect the expression
profiles of these UGT2 enzymes (Harbourt et al., 2012;
Fallon et al., 2013a,b; Sato et al., 2014; Margaillan et al.,
2015a,b; Tourancheau et al., 2016). Our current study offers
a representative view of the endogenous UGT1A enzyme
interactome in relevant drug metabolizing tissues. Findings
are consistent with the interactions between several UGT1A
enzymes and UGT2B7 detected in microsomes from liver
tissues (Fremont et al., 2005; Fujiwara and Itoh, 2014) and
when overexpressed in heterologous cell model systems as
tagged proteins (Kurkela et al., 2007; Operaña and Tukey, 2007;
Fujiwara et al., 2010; Ishii et al., 2010, 2014; Liu et al., 2016). In
addition, other transferases and anti-oxidant PRDX1, PRDX2
and PRDX3 enzymes were also found associated with UGT1A
enzymes. The interaction network is also in line with a model
favoring detoxifying enzymes acting in a “metabolosome,” i.e.
a complex of xenobiotic-metabolizing enzymes and associated
transport proteins regulating drug and xenobiotics inactivation
and elimination (Taura et al., 2000; Takeda et al., 2005a,b, 2009;
Akizawa et al., 2008; Mori et al., 2011; Fujiwara and Itoh, 2014;
Ishii et al., 2014; Rouleau et al., 2014; Fujiwara et al., 2016).
The significant number of peroxisomal and mitochondrial
enzymes regulating fatty acid β-oxidation identified in protein
complexes with UGT1A enzymes hinted toward a potential
involvement of UGT1A in regulating lipid metabolism. The
higher number of lipid droplets, a reservoir of neutral lipids
(such as fatty acids, sterol esters and phospholipids) (Thiam
et al., 2013), in the UGT negative kidney cell model HEK293
overexpressing UGT1A9 lends support to this hypothesis. This
observation is reminiscent of higher levels of lipid bodies induced
by the overexpression of the peroxisomal ACOT8 protein, a
confirmed UGT1A protein partner (Ishizuka et al., 2004). A
modulation of lipid storage levels by overexpression of the
UGT2B7 enzyme was also recently uncovered in breast and
pancreatic cancer cell line models (Dates et al., 2015). This
potential functional link between UGTs and lipid metabolism is
intriguing and may be independent of the glucuronidation of
some bioactive lipids previously reported (Turgeon et al., 2003).
The underlying mechanism(s) of increased lipid droplets and
the potential involvement of protein complexes comprised of
UGT1A enzymes thus remain to be addressed and are aspects
that fall beyond the scope of this study.
While UGT1A are ER-resident enzymes, their presence
in other subcellular compartments such as the mitochondria
is suggested by their co-localization with markers of several
organelles (Rouleau et al., 2016). An intimate connection
between ER, mitochondria, peroxisomes, and lipid droplets
is also well recognized (Currie et al., 2013; Schrader et al.,
2015). This is consistent with the significant number of
peroxisomal and mitochondrial proteins interacting with
UGT1A enzymes. Indeed, peroxisomes and lipid droplets are
ER-derived substructures, whereas interactions between the ER
and mitochondria at the so-called mitochondria-associated ER
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membranes are gaining recognition as important sites of ER-
mitochondria crosstalk where regulation of calcium signaling,
lipid transport and tricarboxylic acid cycle take place (Hayashi
et al., 2009; Tabak et al., 2013; Lodhi and Semenkovich, 2014; Pol
et al., 2014).
The UGT1A interaction network exposes multiple links
with enzymes of bioenergetic pathways. Besides lipids, glycogen
catabolism as well as glycolytic and tricarboxylic acid cycle
pathways may be influenced by the interactions of UGT1A with
several subunits of the phosphorylase b and glycolytic/TCA cycle
enzymes. It could be envisioned that UGT1A enzymes participate
in the regulation of metabolite levels to prevent the toxic impact
of excess concentrations of basic constituents, a hypothesis that
remains to be addressed. Interestingly, mice with a disrupted
UGT1 gene locus (UGT1−/−mice) are short-lived, dying within 1
week of birth. Whereas hyperbilirubinemia induced by UGT1A1
deficiency appears largely responsible for early death, highly
perturbed hepatic expression of genes involved in general cellular
metabolic function, and notably those of starch, sugar and fatty
acid metabolism was also observed in UGT1−/− mice, also
supporting a contribution of UGT1A enzymes in those metabolic
pathways (Nguyen et al., 2008). Rodent cell models fromUGT1A-
deficient mice or Gunn rats may constitute valuable models to
investigate the interplay between UGT1A enzymes and global
metabolic pathways.
One of the limitations of this study is that it examines
complexes in which UGT1A enzymes reside and it does not
provide information on direct interactions of UGT1A with
proteins. Approaches such as proximity ligation and fluorescence
resonance energy transfer are necessary to move forward with
a better understanding of direct protein interactions and the
domains involved. It is well documented that UGTs, like
numerous metabolic enzymes, homo- and hetero-oligomerize
with other UGTs (Fujiwara et al., 2007a; Kurkela et al., 2007;
Operaña and Tukey, 2007; Bellemare et al., 2010b). It is therefore
conceivable that UGT1A enzymes influence the activity of other
metabolic enzymes by direct interactions that could alter the
stoichiometry or composition of metabolic protein complexes.
In turn, interactions of UGT1A enzymes with other metabolic
enzymes may influence the glucuronidation pathway and thus
contribute to the variable conjugation rates of individuals. This
notion is supported by the altered activity of several UGT1A
enzymes by CYP3A4 demonstrated in a cell-based system (Ishii
et al., 2014). As well, the antagonistic or stimulatory functions
of interactions among UGT1A and UGT2 enzymes, or with
alternatively spliced isoforms, are consistent with a potential
mode of regulation of UGTs by PPI (Fujiwara et al., 2007a;
Bellemare et al., 2010b; Bushey and Lazarus, 2012; Rouleau et al.,
2014, 2016; Audet-Delage et al., 2017).
In summary, we established an effective affinity purification
method coupled to mass spectrometry for the enrichment and
identification of protein complexes interacting with endogenous
UGT1A enzymes. We successfully applied this approach to
UGT1A enzymes expressed in drug metabolizing tissues and
a UGT positive cell model to uncover an interaction map
linking glucuronidation enzymes to other metabolic proteins
involved in detoxification, as well as in the regulation of
bioenergetic molecules (lipids and carbohydrates). Our data
also support physical and functional interactions between ER
and other subcellular compartments. The crosstalk among
cellular metabolic functions exposed in this work warrants
future investigations to address the impact of UGT1A-protein
interactions on detoxification functions of UGT1A enzymes and
of UGT1A enzymes on global metabolic cellular functions.
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